Market Cap : 807.55 M | Enterprise Value : 639.33 M | PE Ratio : At Loss | PB Ratio : 1.31 |
---|
NAS:SLGC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:SLGC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. SomaLogic's Cash Ratio for the quarter that ended in Mar. 2022 was 23.43.
SomaLogic has a Cash Ratio of 23.43. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for SomaLogic's Cash Ratio or its related term are showing as below:
During the past 2 years, SomaLogic's highest Cash Ratio was 30.87. The lowest was 11.51. And the median was 22.95.
The historical data trend for SomaLogic's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, SomaLogic's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's Cash Ratio distribution charts can be found below:
* The bar in red indicates where SomaLogic's Cash Ratio falls into.
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
SomaLogic's Cash Ratio for the fiscal year that ended in Dec. 2021 is calculated as:
Cash Ratio (A: Dec. 2021 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 657.706 | / | 29.285 | |
= | 22.46 |
SomaLogic's Cash Ratio for the quarter that ended in Mar. 2022 is calculated as:
Cash Ratio (Q: Mar. 2022 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 647.809 | / | 27.653 | |
= | 23.43 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of SomaLogic's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Blakeman Shaun M. | officer: Chief Financial Officer | C/O CANTEL MEDICAL CORP. 150 CLOVE ROAD LITTLE FALLS NJ 07424 |
Margulies Anne H. | director | C/O HENRY SCHEIN, INC. 135 DURYEA ROAD MELVILLE NY 11747 |
Post Richard A | director | 998 LACOSTA LANE LANE TREE CO 80124 |
Casdin Eli | director | 1350 AVENUE OF THE AMERICAS SUITE 1140 NEW YORK NY 10019 |
Cox Troy | director | C/O FOUNDATION MEDICINE, INC. C/O FOUNDATION MEDICINE, INC., 150 SECON CAMBRIDGE MA 02141 |
Meisel Ted D | director | |
Barchi Robert | director | |
Quake Stephen | director | C/O FLUIDIGM CORPORATION 7000 SHORELINE COURT, SUITE 100 SOUTH SAN FRANCISCO CA 94080 |
Lillis Charles M. | director | 13 CASTLE PINES DRIVE N CASTLE ROCK CO 80108 |
Harris Melody | officer: President and COO | 4801 WEST BYRON PLACE DENVER CO 80211 |
Gutierrez Ruben | officer: General Counsel | 6435 AVENIDA WILFREDO LA JOLLA CA 92037 |
Graves Amy | officer: Chief Accounting Officer | 926 PENDLETON AVENUE LONGMONT CO 80504 |
Smythe Roy | director, officer: Chief Executive Officer | 935 10TH STREET BOULDER CO 80302 |
M-lsh Ii Llc | 10 percent owner | 667 MADISON AVENUE C/O CORVEX MANAGEMENT LP NEW YORK NY 10065 |
C-lsh Ii Llc | 10 percent owner | 1350 6TH AVENUE SUITE 2600 NEW YORK NY 10019 |
From GuruFocus
Other Sources
By Seekingalpha 2021-10-14
By Zacks 2022-02-17
By Seekingalpha 2022-01-11
By Seekingalpha 2021-11-15